Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/203826
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia |
Autor: | DeAngelo, Daniel J.; Walker, Alison R.; Schlenk, Richard F.; Sierra, Jorge; Medeiros, Bruno C.; Ocio, Enrique M. CSIC ORCID ; Röllig, Christoph; Stricklandh, Stephen A.; Thol, Felicitas; Valera, Sue-zette; Dasgupta, Kohinoor; Berkowitz, Noah; Stuart, Robert K. | Palabras clave: | Panobinostat Idarubicin Cytarabine Acute myeloid leukemia AML |
Fecha de publicación: | oct-2019 | Editor: | Elsevier | Citación: | Leukemia Research 85: 106197 (2019) | Resumen: | The role of histone deacetylase inhibitors in the treatment of acute myeloid leukemia (AML) is not well characterized. The current study evaluated the safety and efficacy of panobinostat in combination with idarubicin and cytarabine in newly diagnosed patients aged ≤65 years with primary or secondary high-risk AML based on cytogenetic classification. Treatment included fixed dose idarubicin (12 mg/m2/d, IV; day 1–3) and cytarabine (100 mg/m2/d, continuous IV infusion; day 1–7) and escalating oral doses of panobinostat at 15 mg, 20 mg, and 25 mg, thrice weekly starting at week 2 of a 28-day cycle. Forty-six patients were enrolled (primary AML [n = 36], secondary AML [n = 10]). The median age was 55 years. The most common all-grade AEs were diarrhea (54.3%), nausea (39.1%), vomiting, and decreased appetite (each, 21.7%), stomatitis (19.6%), and fatigue (17.4%). The overall response rate was 60.9%, 43.5% achieved a complete remission (CR), and 17.4% achieved CR with incomplete count recovery. The event-free survival at 1-year was 78.3%. Panobinostat in combination with idarubicin and cytarabine demonstrated tolerable safety and efficacy in younger patients with high-risk AML. The recommended phase 2 dose of panobinostat in this combination was 20 mg. ClinicalTrials.gov registry no: NCT01242774, and European Trial Registry EudraCT no: 2009-016809-42. | Versión del editor: | http://dx.doi.org/10.1016/j.leukres.2019.106197 | URI: | http://hdl.handle.net/10261/203826 | DOI: | 10.1016/j.leukres.2019.106197 | ISSN: | 0145-2126 | E-ISSN: | 1873-5835 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
10
checked on 22-feb-2024
SCOPUSTM
Citations
12
checked on 25-abr-2024
WEB OF SCIENCETM
Citations
11
checked on 27-feb-2024
Page view(s)
138
checked on 23-abr-2024
Download(s)
49
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.